that is oblivious to the mechanisms bacteria have evolved to resist traditional antibiotics, and because of their tailorable specificity, they can be directed against specific species or strains with minimal or no off-target effects.

The company currently has in development Avidocin agents targeting 10 different organisms including threatening human pathogens such as C. difficile, uropathogenic E. coli, and K. pneumonia. Pre-clinical animal studies have demonstrated that Avidocin proteins can be orally or parentally administered to prevent or treat disease with impressive efficacy in multiple infection models.